肾细胞癌干细胞标志物研究进展

doi:10.3760/cma.j.issn.1673-422X.2014.09.009

摘要/Abstract

摘要： 肾细胞癌干细胞决定了肾细胞癌的生长和增殖，目前已发现的肾细胞癌潜在标志物包括八聚体序列结合因子4（Oct4）、CD133、CD105、ATP结合盒B亚家族成员1转运蛋白基因（ABCB1）、趋化因子受体4（CXCR4），但这些分子标志物仍然存在争议。因此，迫切需要研究证实普遍适用的肾细胞癌标志物，以针对其更加有效地治疗肾细胞癌。

关键词: 癌, 肾细胞, 肿瘤干细胞, 生物学标记

Abstract: The renal cell cancer stem cells determine the growth and proliferation of renal cell carcinoma. So far some possible markers have been identified in renal cell carcinoma, including octamer binding factor 4 (Oct4), CD133, CD105, ATPbinding cassette subfamily B member 1 transporter gene (ABCB1), CXC chemokine receptor 4 (CXCR4), but these markers are still controversial. Therefore, for the more effective treatments of metastatic renal cell carcinoma, studying a generally applicable marker for renal cell carcinoma is necessary.

Key words: Carcinoma, renal cell, Neoplastic stem cells, Biological markers

黄亮亮,王德林. 肾细胞癌干细胞标志物研究进展[J]. 国际肿瘤学杂志, 2014, 41(8): 668-671.

Huang Liangliang, Wang Delin. Markers of renal cell carcinoma stem cells[J]. Journal of International Oncology, 2014, 41(8): 668-671.

参考文献

［1］ Siegel R, Naishadham D, Jemal A. Cancer statistics, 2013［J］. CA Cancer J Clin, 2013, 63(1): 11-30. ［2］ Chen L, Kasai T, Li Y, et al. A model of cancer stem cells derived from mouse induced pluripotent stem cells［J］. PLoS One, 2012, 7(4): e33544. ［3］ Kellner S, Kikyo N. Transcriptional regulation of the Oct4 gene, a master gene for pluripotency［J］. Histol Histopathol, 2010, 25(3): 405-412. ［4］ Gupta S, Verfaillie C, Chmielewski D, et al. Isolation and characterization of kidneyderived stem cells［J］. J American Soc Nephrol, 2006, 17(11): 3028-3040. ［5］ Looijenga LH, Stoop H, de Leeuw HP, et al. POU5F1 (OCT3/4) identifies cells with pluripotent potential in human germ cell tumors［J］. Cancer Res, 2003, 63(9): 2244-2250. ［6］ Raman JD, Mongan NP, Liu L, et al. Decreased expression of the human stem cell marker, Rex1 (zfp42), in renal cell carcinoma［J］. Carcinogenesis, 2006, 27(3): 499-507. ［7］ Bussolati B, Moggio A, Collino F, et al. Hypoxia modulates the undifferentiated phenotype of human renal inner medullary CD133＋ progenitors through Oct4/miR145 balance［J］. Am J Physiol Renal Physiol, 2012, 302(1): F116-128. ［8］ Gazda LS, Martis PC, Laramore MA, et al. Treatment of agaroseagarose RENCA macrobeads with docetaxel selects for OCT4(＋) cells with tumorinitiating capability［J］. Cancer Biol Ther, 2013, 14(12): 1147-1157. ［9］ Abad M, Mosteiro L, Pantoja C, et al. Reprogramming in vivo produces teratomas and iPS cells with totipotency features［J］. Nature, 2013, 502(7471): 340-345. ［10］ Yin AH, Miraglia S, Zanjani ED, et al. AC133, a novel marker for human hematopoietic stem and progenitor cells［J］. Blood, 1997, 90(12): 5002-5012. ［11］ Bussolati B, Bruno S, Grange C, et al. Isolation of renal progenitor cells from adult human kidney［J］. Am J Pathol, 2005, 166(2): 545-555. ［12］ Angelotti ML, Ronconi E, Ballerini L, et al. Characterization of renal progenitors committed toward tubular lineage and their regenerative potential in renal tubular injury［J］. Stem Cells, 2012, 30(8): 1714-1725. ［13］ Bruno S, Bussolati B, Grange C, et al. CD133＋ renal progenitor cells contribute to tumor angiogenesis［J］. Am J Pathol, 2006, 169(6): 2223-2235. ［14］ Addla SK, Brown MD, Hart CA, et al. Characterization of the Hoechst 33342 side population from normal and malignant human renal epithelial cells［J］. Am J Physiol Renal Physiol, 2008, 295(3): F680-687. ［15］ Costa WH, Rocha RM, Cunha IW, et al. CD133 immunohistochemical expression predicts progression and cancerrelated death in renal cell carcinoma［J］. World J Urol, 2012, 30(4): 553-558. ［16］ Kim K, Ihm H, Ro JY, et al. Highlevel expression of stem cell marker CD133 in clear cell renal cell carcinoma with favorable prognosis［J］. Oncol Lett, 2011, 2(6): 1095-1100. ［17］ Fonsatti E, Nicolay HJ, Altomonte M, et al. Targeting cancer vasculature via endoglin/CD105: a novel antibodybased diagnostic and therapeutic strategy in solid tumours［J］. Cardiovasc Res, 2010, 86(1): 12-19. ［18］ Bussolati B, Dekel B, Azzarone B, et al. Human renal cancer stem cells［J］. Cancer Lett, 2013, 338(1): 141-146. ［19］ Bussolati B, Bruno S, Grange C, et al. Identification of a tumorinitiating stem cell population in human renal carcinomas［J］. FASEB J, 2008, 22(10): 3696-3705. ［20］ Dubinski W, Gabril M, Iakovlev VV, et al. Assessment of the prognostic significance of endoglin (CD105) in clear cell renal cell carcinoma using automated image analysis［J］. Hum Pathol, 2012, 43(7): 1037-1043. ［21］ Huang B, Huang YJ, Yao ZJ, et al. Cancer stem celllike side population cells in clear cell renal cell carcinoma cell line 769P［J］. PLoS One, 2013, 8(7): e68293. ［22］ Goodell MA, Brose K, Paradis G, et al. Isolation and functional properties of murine hematopoietic stem cells that are replicating in vivo［J］. J Exp Med, 1996, 183(4): 1797-1806. ［23］ Nishizawa S, Hirohashi Y, Torigoe T, et al. HSP DNAJB8 controls tumorinitiating ability in renal cancer stemlike cells［J］. Cancer Res, 2012, 72(11): 2844-2854. ［24］ Lu J, Cui Y, Zhu J, et al. Biological characteristics of Rh123high stem like cells in a side population of 786O renal carcinoma cells［J］. Oncol Lett, 2013, 5(6): 1903-1908. ［25］ Ratajczak MZ, ZubaSurma E, Kucia M, et al. The pleiotropic effects of the SDF1CXCR4 axis in organogenesis, regeneration and tumorigenesis［J］. Leukemia, 2006, 20(11): 1915-1924. ［26］ Gassenmaier M, Chen D, Buchner A, et al. CXC chemokine receptor 4 is essential for maintenance of renal cell carcinomainitiating cells and predicts metastasis［J］. Stem Cells, 2013, 31(8): 1467-1476. ［27］ Cojoc M, Peitzsch C, Trautmann F, et al. Emerging targets in cancer management: role of the CXCL12/CXCR4 axis［J］. Onco Targets Ther, 2013, 6: 1347-1361. ［28］ Wend P, Holland JD, Ziebold U, et al. Wnt signaling in stem and cancer stem cells［J］. Semin Cell Dev Biol, 2010, 21(8): 855-863. ［29］ Saito N, Fu J, Zheng S, et al. A high notch pathway activation predicts response to γ secretase inhibitors in proneural subtype of glioma tumorinitiating cells［J］. Stem Cells, 2014, 32(1): 301-312. ［30］ Bartucci M, Dattilo R, Moriconi C, et al. TAZ is required for metastatic activity and chemoresistance of breast cancer stem cells［J］. Oncogene, 2014, In press.

[1]	钱晓涛, 石子宜, 胡格, 吴晓维. Ⅲ~ⅣA期食管鳞状细胞癌放化疗后行巩固化疗的疗效：一项真实世界临床研究[J]. 国际肿瘤学杂志, 2024, 51(6): 326-331.
[2]	郭泽浩, 张俊旺. PFDN及其亚基在肿瘤发生发展中的作用[J]. 国际肿瘤学杂志, 2024, 51(6): 350-353.
[3]	王丽, 刘志华, 杨伟洪, 蒋凤莲, 李全泳, 宋浩杰, 鞠文东. ROS1突变肺腺鳞癌合并脑梗死为主要表现的Trousseau综合征1例[J]. 国际肿瘤学杂志, 2024, 51(6): 382-384.
[4]	范志鹏, 余静, 胡静, 廖正凯, 徐禹, 欧阳雯, 谢丛华. 炎症标志物的变化趋势对一线接受免疫联合化疗的晚期非小细胞肺癌患者预后的预测价值[J]. 国际肿瘤学杂志, 2024, 51(5): 257-266.
[5]	王俊毅, 洪楷彬, 纪荣佳, 陈大朝. 癌结节对结直肠癌根治性切除术后肝转移的影响[J]. 国际肿瘤学杂志, 2024, 51(5): 280-285.
[6]	顾芳萌, 徐晨阳, 雷大鹏. 人工智能辅助电子喉镜检查在喉癌及喉癌前病变诊治中的研究进展[J]. 国际肿瘤学杂志, 2024, 51(5): 303-307.
[7]	张文馨, 夏泠, 彭晋, 周福祥. 甲胎蛋白升高型胃肝样腺癌1例并文献复习[J]. 国际肿瘤学杂志, 2024, 51(5): 312-315.
[8]	王昆, 周中新, 臧其威. 血清TGF-β1、VEGF水平对非小细胞肺癌患者单孔胸腔镜根治术后复发的预测价值[J]. 国际肿瘤学杂志, 2024, 51(4): 198-203.
[9]	杨毫, 施贵冬, 张程城, 张跃, 张力文, 付茂勇. 信迪利单抗与替雷利珠单抗在进展期食管鳞状细胞癌新辅助治疗中的疗效及安全性对比[J]. 国际肿瘤学杂志, 2024, 51(4): 210-216.
[10]	姚益新, 沈煜霖. 血清SOCS3、TXNIP水平对肝细胞癌TACE治疗预后的预测价值[J]. 国际肿瘤学杂志, 2024, 51(4): 217-222.
[11]	胡婷婷, 王越华. 电子鼻与线虫鼻——新型早期癌症筛查工具[J]. 国际肿瘤学杂志, 2024, 51(4): 223-226.
[12]	张栋岩, 王品, 魏秋亚, 邓成伍, 魏相相, 高远飞, 王琛. 索凡替尼靶向联合卡培他滨和奥沙利铂治疗肝内胆管癌术后患者1例及文献复习[J]. 国际肿瘤学杂志, 2024, 51(4): 249-253.
[13]	严爱婷, 王翠竹, 刘春桂, 鲁小敏. 卡瑞利珠单抗与信迪利单抗治疗晚期非小细胞肺癌的临床疗效及安全性分析[J]. 国际肿瘤学杂志, 2024, 51(3): 137-142.
[14]	孙维蔚, 姚学敏, 王鹏健, 王静, 贾敬好. 基于血液学指标探讨免疫治疗晚期非小细胞肺癌预后因素及列线图构建[J]. 国际肿瘤学杂志, 2024, 51(3): 143-150.
[15]	钱晓涛, 石子宜, 胡格. Ⅲ~ⅣA期食管鳞状细胞癌根治性放化疗后行免疫检查点抑制剂维持治疗的真实世界临床研究[J]. 国际肿瘤学杂志, 2024, 51(3): 151-156.